Tailoring radiotherapy in cT1-2N1 breast cancer to nodal response on primary chemotherapy (RAPCHEM: BOOG 2010-03): 10-year follow-up results of a Dutch, prospective, registry study.

Saved in:
Bibliographic Details
Title: Tailoring radiotherapy in cT1-2N1 breast cancer to nodal response on primary chemotherapy (RAPCHEM: BOOG 2010-03): 10-year follow-up results of a Dutch, prospective, registry study.
Authors: Mauritz AJW; Department of Radiation Oncology Maastro, GROW Research Institute for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, Netherlands. Electronic address: fleur.mauritz@maastro.nl., de Munck L; Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands., Simons JM; Department of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands., Verloop J; Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands., van Dalen T; Department of Surgery, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands., Elkhuizen PHM; Department of Radiation Oncology, Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands., Scholten A; Department of Radiation Oncology, Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands., Houben RMA; Department of Radiation Oncology Maastro, GROW Research Institute for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, Netherlands., van Leeuwen-Stok AE; Dutch Breast Cancer Research Group, Utrecht, Netherlands., Linn SC; Department of Medical Oncology, Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands; Department of Pathology Cancer, University Medical Centre Utrecht, Utrecht, Netherlands., Pijnappel RM; Department of Radiology, University Medical Centre Utrecht, Utrecht, Netherlands., Poortmans PMP; Department of Radiation Oncology, Iridium Netwerk, Wilrijk-Antwerp, Belgium; Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk-Antwerp, Belgium., Strobbe LJA; Department of Surgery, Canisius Wilhelmina Hospital Nijmegen, Nijmegen, Netherlands; Early Detection Centre, Netherlands Cancer Institute, Amsterdam, Netherlands., Wesseling J; Department of Pathology, Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Pathology, Leiden University Medical Centre, Leiden, Netherlands., Voogd AC; Department of Epidemiology, GROW Research Institute for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, Netherlands; Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands., Boersma LJ; Department of Radiation Oncology Maastro, GROW Research Institute for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, Netherlands.
Source: The Lancet. Oncology [Lancet Oncol] 2026 Jul; Vol. 27 (7), pp. 808-816.
Publication Type: Journal Article; Multicenter Study; Observational Study
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-5488
DOI:10.1016/S1470-2045(26)00216-0